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nance of CLP in vivo. The IL-7R is comprised of the IL-7R and c
chains. Besides the IL-7R, the c is a component of the receptors
for IL-2, IL-4, IL-9, IL-15, and IL-21. Mice which lack the IL-7R
or c have profound defects in thymopoiesis and are lymphopenic.
C-kit loss-of-function mutants have modest decreases (50%) in
thymic cellularity. Mice doubly mutated for the W41 mutation of
the c-kit catalytic domain, and either null mutations of IL-7,
IL-7R, or c have synergistic blocks in thymopoiesis, and signiﬁ-
cantly decreased numbers of B lymphocytes, consistent with an
effect on CLP. In order to determine the receptors regulating the
CLP pool, the quantity of phenotypic CLP were measured in
C57BL/6J mice with mutations in IL-7, c, c-kit, and a combina-
tion of c-/-KitW41/W41. Control C57BL/6J (B6) mice have approx-
imately 10,500  3,280 CLP per femur. There was a 1.5-2-fold
reduction in CLP frequency for singly mutated strains (7,740 
3,750 in IL-7-/-, 5,040  3,730 in c-/-, 6,530  959 in KitW41/W41,
p  .05 vs B6). c-/-/KitW41/W41 showed an approximately fourfold
decrease, with 2,320  1,070 CLP per femur (P  .05 vs. all other
strains). The decreased CLP in IL-7-/- mice was not as profound as
in the c-/- mice (p  .05 for IL-7-/- vs c-/-), suggesting that either
another c ligand, or another receptor (e.g. c-kit), partially com-
pensates for the lack of IL-7. The decline in CLP numbers was not
due to a global decrease in lymphohematopoiesis, as the number of
marrow cells did not differ signiﬁcantly between strains. The
identiﬁcation of the c-kit and IL-7R as important in survival and
maintenance of CLP is a critical step for the development of strategies
for expansion of lymphoid progenitors for transplantation.
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TRANSIENT HUMAN MEGAKARYOPOIESIS AND PLATELET PRODUC-
TION FOLLOWING UMBILICAL CORD BLOOD TRANSPLANTATION INTO
NOD/SCID MICE
Cogle, C.R., Wainman, D.A., Rimsza, L.S., Sola, M.C., Scott, E.W.,
Slayton, W.B. University of Florida, Gainesville, FL
Umbilical cord blood (UCB) provides a readily available and
effective source of hematopoietic stem cells for the treatment of
malignancies, marrow failure syndromes, and metabolic disorders.
However, prolonged thrombocytopenia is a major complication
after UCB transplantation. In vivo animal models characterizing
human megakaryocyte engraftment after UCB transplantation
have been lacking. Chimeric mice were generated by sublethally
irradiating recipient non-obese diabetic severe combined immuno-
deﬁcient (NOD/scid) mice followed by intravenous injection of
human CD34 cells greatly enriched for hematopoietic stem cells
(HSC)/hematopoietic progenitor cells (HPC) from UCB. A min-
imum of 5 animals was transplanted per time point. At four to six
weeks after xenotransplantation, approximately 60% of NOD/scid
mice had human hematopoietic reconstitution in peripheral blood,
and 90% were chimeric in bone marrow. Additionally, examination
of murine bone marrow and peripheral blood after transplantation
demonstrated human megakaryocyte engraftment and platelet pro-
duction. More speciﬁcally, our results are consistent with a prior
report describing transient human platelet production following
adult PBSC transplantation. Peak peripheral blood platelet pro-
duction occurred at 6 weeks post-transplant with up to 0.63%
human platelet chimerism. To determine the cause of this transient
platelet production UCB grafts were analyzed for contaminating
platelets and found to have none. Moreover, assay of mouse spleens
demonstrated no human platelet sequestration. Secondary trans-
plantation studies are ongoing to determine if engraftment is from
HPC or HSC activity. To explore UCB-derived megakaryocyte
proliferation and differentiation, we used direct immunostaining
and found robust, albeit transient megakaryocyte chimerism in
NOD/scid mouse bone marrow, also peaking at 6 weeks. Further-
more, immunohistochemistry studies demonstrate some of these
UCB-derived megakaryocytes as small and often lacking podocytes
–morphologic characteristics of immaturity. This report estab-
lishes the NOD/scid mouse xenotransplant model to study human
megakaryopoiesis and platelet production after UCB transplanta-
tion. Given the clinical signiﬁcance of delayed platelet engraftment
after UCB transplantation, this preclinical mouse model provides a
system to further assay the molecular mechanism of UCB-derived
megakaryocyte engraftment, development, and platelet release.
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HUMAN BONE MARROW-DERIVED CD133 CELLS CAN BE EX-
PANDED EX-VIVO IN THE PRESENCE OF A POLYAMINE COPPER
CHELATOR
Grynspan, F.1, Landau, E.1, Marikovsky, M.1, Yudin, D.1, Nagler, A.2,
Hasson, A.1, Bulvik, S.3 1. Gamida-Cell Ltd., Jerusalem, Israel; 2.
Hematology, Cord Blood Bank, Chaim Sheba Medical Center, Tel Aviv
University, Tel Hashomer, Tel-aviv, Israel; 3. Hematology Department,
Laniado Hospital, Netanya, Israel
The capacity of the polyamine copper chelator tetraethylenepen-
tamine (TEPA) to induce a marked expansion of human cord
blood-derived CD34 cells was previously demonstrated (Peled
T. et al 2002, Br. J. of Haematology 116:655-661). To examine the
effect of TEPA also on the ex-vivo expansion of bone marrow
(BM)-derived stem cells, we have isolated AC133 cells from fresh
human BM at purities greater than 90% as measured by FACS.
Cell cultures (1104/ml) were expanded in Teﬂon bags, in the
presence of IL-6, TPO, Flt3 ligand and SCF with or without
TEPA (5 uM) for 3 weeks and further incubated with cytokines
only. Cell types were analyzed by FACS. Total mononuclear cell
(TMC) expansion was 1216  176-fold after 5 weeks in TEPA-
treated cultures, representing a 2.5- fold higher expansion level as
compared to a cytokines-treated control population. 3-weeks old
cultures displayed similar amounts of CD34 and AC133 cells,
irrelevant of treatment. However, following 5 weeks of ex-vivo
expansion, TEPA-treated cultures exhibited a signiﬁcant increase
(16.5–fold) in AC133 cells and in CD34 cells (105–fold) expan-
sion, as compared to a cytokines-treated control population. In
addition, CFU following 5 weeks ex-vivo expansion was 21.4
higher in TEPA-treated cultures, as compared to a cytokines-
treated control population. Signiﬁcantly, the number of AC133/
CD38- cells following 3 weeks ex-vivo expansion was 26-fold, as
compared to a cytokines-treated control population. The data
presented here strengthen the usefulness of copper chelators to
induce proliferation of early progenitors that inﬂuence the
long term survival and proliferation of early subset popula-
tions which are especially reduced in bone marrow as compared
to cord blood. The potential of TEPA for increased ex-vivo
expansion of long term capacity stem cells derived from sources
other than cord blood can provide stem cell-based therapies plat-
form for the autologous treatment of vascular, cardiovascular,
diabetes, hepatic, neurodegenerative, skeletal, and other clinical
indications.
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UMBILICAL CORD BLOOD CELLS ENGRAFT AND DIFFERENTIATE IN
CARDIAC TISSUES AFTER HUMAN TRANPLANTATION
Crapnell, K.B., Turner, K., Hall, J., Staba, S., Kurtzberg, J. Duke
University Medical Center, Durham, NC
Introduction: Umbilical cord blood (UCB) stem cells can suc-
cessfully rescue the blood and immune system after myeloblative
transplantation. Preclinical studies have shown that hematopoietic
cells from bone marrow and umbilical cord blood have the ability
to “transdifferentiate” into tissue other then those speciﬁed by
their origin. We asked whether hematopoietic stem cells from
UCB have the ability to differentiate into cardiac muscle in trans-
planted patients with pre-existing cardiac pathology. Methods: An
unfortunate child with Sanﬁlippo Syndrome Type B (Mucopo-
lysaccharide (MPS) III) transplanted with a sex mismatched unre-
lated UCB unit at 4 years of age, engrafted but died 5 months
post-transplant of respiratory failure due to an adenoviral infec-
tion. With parental consent, his heart was studied in order to
determine whether donor derived cells had engrafted and/or dif-
ferentiated at the time of his death. At autopsy heart tissue was
ﬁxed in formalin, embedded in parafﬁn, and stored for future
evaluation. Approximately 2 months later, cardiac tissue was cut
into 5 micron thick sections, dehydrated, and stained with anti-
bodies (Troponin I-C and myosin heavy chain) against cardiac
speciﬁc antigens. These same heart sections were then counter-
stained with FISH for XY chromosomes to differentiate donor and
host cells. Results: We found extensive distribution of female
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donor cells in blood vessels throughout the heart (63% of total cells
enumerated). Rarer donor cells were also found through the myo-
cardium in cells with patterns exhibiting the cross-striations of
striated muscle. Donor cells stained positive for Troponin I-C
(speciﬁc for cardiac muscle Troponin I) and for myosin heavy
chain (1-2 cells per 10-20 high power ﬁelds). Conclusion: We
documented engraftment and differentiation of donor UCB cells
into cardiac myocytes in a child transplanted for MPS III. It is
possible that donor cells may selectively homed to damaged myo-
cardium and subsequently differentiated in situ. After engraftment,
differentiation into myocardial cells may improve cardiac function
and subsequently diminish the likelihood of progressive heart fail-
ure with its attendant morbidity and mortality in patients with
MPS syndromes.
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LOWER POST-TRANSPLANT SERUM ALBUMIN LEVELS PREDICT SIG-
NIFICANTLY POORER SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Pedicano, J., Verma, A., Tomblyn, M., Gordon, L., Singhal, S., Tall-
man, M., Williams, S., Winter, J., Mehta, J. Northwestern University,
Chicago
Low serum albumin is a non-speciﬁc but powerful indicator of
poorer outcome in elderly and hospitalized patients, after surgery,
and in several other circumstances including on routine testing
(Goldwasser Feldman, J Clin Epidemiol 1997;50:693-703). Based
upon the observation that patients with signiﬁcant complications
after transplantation usually have lower albumin levels and those
with higher albumin levels are usually well, we analyzed the rela-
tionship between post-transplant albumin levels and overall sur-
vival in recipients of non-myeloablative allogeneic transplantation
(NMAT). Overall survival (OS) was chosen as an endpoint rather
than disease-free survival because a number of patients relapsing
after NMAT attain remission again and survive long-term, and a
higher albumin level after relapse may be a predictor of better
outcome too. 47 consecutive NMAT recipients with hematologic
malignancies (27-66 years; median 51) were studied. The condi-
tioning regimen was 100 mg/m2 melphalan on day -1 ( 50 mg/kg
cyclophosphamide on day -2 if no prior autograft), cyclosporine
(HLA-matched sibling donor; n  32) or tacrolimus (1-locus
mismatched sibling donor; n 3, or unrelated donor; n 12), and
mycophenolate mofetil. Albumin levels on days 0, 30, 60 and 90,
and average albumin levels over weeks 1-2, 3-4, 5-6, 7-8, 9-10,
11-12, and 13-16 were analyzed. All comparisons were for 3 vs
3 g/dL except weeks 1-2 and 3-4 where a 2.5 vs 2.5 g/dL
cut-off was used because most patients had relatively low albumin
levels for the ﬁrst month. In each of the 11 comparisons, the group
with the lower albumin level had a lower probability of OS at 18
months. The table shows the OS differences were statistically
signiﬁcant. This analysis conﬁrms our clinical impression of the
poor prognostic implication of low albumin levels after allogeneic
transplantation. Further work is required to explore how the out-
come of patients with low albumin can be improved by modifying
medical management.
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TEMPO OF NEUTROPHIL RECOVERY AND THE DEFINITION OF MY-
ELOID ENGRAFTMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (HSCT) IN PATIENTS NOT RECEIVING
GROWTH FACTORS POST-TRANSPLANT
Naik, P., Verma, A., Pedicano, J., Gordon, L., Singhal, S., Tallman,
M., Williams, S., Winter, J., Mehta, J. Northwestern University,
Chicago
Time to myeloid recovery after HSCT is usually deﬁned as the
ﬁrst of 3 consecutive days with an absolute neutrophil count (ANC)
of 0.5 109/L. HSCT registries and FACT require ANC0.5 for
3 days as adequate evidence of engraftment. The ﬁrst day with
ANC 0.5 can be considered the day of engraftment in autograft
recipients (Bone Marrow Transplant 2002;30:749-752). We have
shown this in 78 allograft recipients too (Rihn et al. ASH 2002).
However, the allograft study was limited by the fact that most
patients had received G-CSF post-transplant, and the stem cell
source was not uniform. We have now studied 49 patients al-
lografted using blood stem cells who did not receive post-trans-
plant G-CSF to see if the tempo of myeloid recovery was sustained.
The conditioning regimen, 100 mg/m2 melphalan ( 50 mg/kg
cyclophosphamide if no prior autograft), induced severe neutrope-
nia (ANC 0.1) in all patients. The CD34 cell dose was 1.4-
11.8  106/kg (median 5.0). The time to ANC 0.5 was 10-23
days (median 13). Potentially acceptable evidence of engraftment,
ANC on the 2 days following an initial value of 0.5, was available
in 46 (94%). The remaining 3 patients had ANC 0.5 for the ﬁrst
and second days but died after that (n  2) or did not have a
differential count available (n  1). ANC increased from day 1 to
2 in 41 of 46 patients, and declined in 5 (0.5 in 2, 0.5 in 3. 2 of
the latter had ANC 0.5 the next day). ANC increased from day
2 to 3 in 44 of 46 patients, and declined in 2 (0.5 in both). ANC
increased from day 1 to 3 in 45 of 46 patients; declining below 0.5
in 1 patient. Thus, in 43 of 46 patients, the ﬁrst day with ANC 0.5
was also the ﬁrst of 3 consecutive days with ANC 0.5. These data
support our previous observations that in the majority of al-
lografted patients, ANC does not decline signiﬁcantly immediately
after recovering to0.5 whether or not myeloid growth factors are
administered post-transplant. Therefore, it is not essential to ob-
tain WBC counts on 3 consecutive days to deﬁne myeloid engraft-
ment. The ﬁrst day with ANC 0.5 should be considered the day
of myeloid engraftment in allograft as well as autograft recipients.
This simple change in deﬁnition and practice has signiﬁcant po-
tential impact on convenience (unnecessary clinic visits for pa-
tients; particularly out-patient mini-allografts), cost (blood counts,
home health visits, ancillary charges), and compliance (acceptable
deﬁnition of engraftment by HSCT registries and FACT).
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INTERACTION BETWEEN DONOR TYPE AND CMV SEROSTATUS ON
MORTALITY AFTER ALLOGENEIC HSCT: DO PREEMPTIVE APPROACHES
WORK EQUALLY FOR ALL?
Nichols, W.G., Gooley, T.A., Boeckh, M. Fred Hutchinson Cancer
Research Center, Seattle, WA
Background: In the current era of effective preemptive antiviral
approaches, cytomegalovirus (CMV) is now a rare cause of early
mortality after hematopoietic stem cell transplantation (HSCT).
Though the direct effects of CMV (such as CMV pneumonia) have
been largely eliminated, many recent cohort studies (reviewed in
Table.
Time
Higher Albumin Lower Albumin
Pn 1-y OS (95% CI) (%) n 1-y OS (95% CI) (%)
Day 60 25 73 (51-94) 13 48 (19-78) 0.01
Weeks 1-2 24 75 (56-94) 23 20 (0-51) 0.01
Weeks 3-4 24 76 (56-97) 22 35 (9-61) 0.01
Weeks 5-6 27 69 (48-90) 17 42 (17-67) 0.02
Weeks 7-8 24 78 (58-97) 14 33 (5-62) 0.003
Weeks 9-10 24 74 (54-94) 11 47 (14-79) 0.05
Table.
Day 1 Day 2 Day 3
ANC (109/L) 0.74 (0.53-2.10) 1.43 (0.36-10.94) 2.46 (0.44-30.74)
Change from
Day 1 (%) 67 (36 to 574) 176 (21 to 1793)
Change from
Day 2 (%) 50 (17 to 1925)
ANC <0.5
(n) 0 3 (7%) 1 (2%)
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